Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Àü¸³¼± ¿ëÀû°ú Àü¸³¼±¾ÏÀÇ ºÐÈ­µµ¿ÍÀÇ »ó°ü°ü°è The Relationship of Prostate Volume and the Grade of Prostate Cancer

´ëÇѺñ´¢±â°úÇÐȸÁö 2007³â 48±Ç 10È£ p.1004 ~ 1009
À¯ÁöÇü, ÀÌÁ¤¿ì, ÀåÀÎÈ£, ÇÑÁØÇö, ÇѺ´±Ô, Á¤¼ºÁø, È«¼º±Ô, º¯¼®¼ö, Ãֱ⿵, ÀÌ»óÀº,
¼Ò¼Ó »ó¼¼Á¤º¸
À¯ÁöÇü ( Yu Ji-Hyeong ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ »ó°è¹éº´¿ø ºñ´¢±â°úÇб³½Ç

ÀÌÁ¤¿ì ( Lee Jeong-Woo ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºñ´¢±â°úÇб³½Ç
ÀåÀÎÈ£ ( Chang In-Ho ) 
ÇÑÀüÀÇ·áÀç´Ü ÇÑÀϺ´¿ø ºñ´¢±â°úÇб³½Ç
ÇÑÁØÇö ( Han Jun-Hyun ) 
ÇÑÀüÀÇ·áÀç´Ü ÇÑÀϺ´¿ø ºñ´¢±â°úÇб³½Ç
ÇѺ´±Ô ( Han Byoung-Kyu ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºÐ´ç¼­¿ï´ëÇб³º´¿ø ºñ´¢±â°úÇб³½Ç
Á¤¼ºÁø ( Jeong Seong-Jin ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºÐ´ç¼­¿ï´ëÇб³º´¿ø ºñ´¢±â°úÇб³½Ç
È«¼º±Ô ( Hong Sung-Kyu ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºÐ´ç¼­¿ï´ëÇб³º´¿ø ºñ´¢±â°úÇб³½Ç
º¯¼®¼ö ( Byun Seok-Soo ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºÐ´ç¼­¿ï´ëÇб³º´¿ø ºñ´¢±â°úÇб³½Ç
Ãֱ⿵ ( Choe Ghee-Young ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ º´¸®Çб³½Ç
ÀÌ»óÀº ( Lee Sang-Eun ) 
¼­¿ï´ëÇб³ ÀÇ°ú´ëÇÐ ºÐ´ç¼­¿ï´ëÇб³º´¿ø ºñ´¢±â°úÇб³½Ç

Abstract

Àü¸³¼±¾ÏÀº Àü±¸ ¾Ï ´Ü°è¿¡¼­ ÀÓ»óÀûÀ¸·Î ÀÇ¹Ì ÀÖ´Â ¾ÏÀÇ ¹ßÇö±îÁö ½Ã°£ÀÌ ¿À·¡ °É¸®°í, Ä¡·á¿Í °ü·ÃµÈ ÀÌȯÀ² ¹× ¹àÇôÁø ºÐÀÚÇÐÀû ¹ßº´±âÀüÀ¸·Î ÀÎÇØ È­ÇÐÀû ¿¹¹æÀÇ ÁÁÀº ´ë»óÀÌ µÉ ¼ö ÀÖ´Ù.1 µû¶ó¼­ Àü¸³¼±¾ÏÀÇ È­ÇÐÀû ¿¹¹æÀ» À§ÇØ ºñŸ¹Î E, selenium, cyclooxygenase (COX)-2¾ïÁ¦Á¦, ºñŸ¹ÎD, soy, selective estrogen receptor modulator (SERMs), lycopen, Áö¹æ°ú ³ìÂ÷ µîÀÌ ¼Ò°³µÇ°í ÀÖ´Ù. ¶ÇÇÑ finasteride, dutasteride¿Í °°Àº ¾àÁ¦µµ ¿¬±¸µÇ¾î ±× °á°ú°¡ ¹ßÇ¥µÈ ¹Ù ÀÖ°í ÀϺδ ÁøÇà Áß¿¡ ÀÖ´Ù.
1993³âºÎÅÍ 7³â µ¿¾È 18,882¸íÀ» ´ë»óÀ¸·Î ÇÑ ´ë´ÜÀ§ ¿¬±¸°á°ú°¡ ¹ßÇ¥µÈ prostate cancer prevention trial (PCPT)Àº finasteride º¹¿ë±º¿¡¼­ À§¾à Åõ¿©±º¿¡ ºñÇØ Àü¸³¼±¾ÏÀÇ ¹ß»ý ºóµµ¸¦ 24.8%¸¸Å­ ÁÙ¿´´Ù´Â Á¡¿¡¼­´Â »ó´çÈ÷ °í¹«ÀûÀ̾úÁö¸¸, »ç¸Á·üÀÌ ³ô°í, ´õ¿í Àû±ØÀûÀÎ Ä¡·á¸¦ ¿äÇÏ´Â °íµî±Þ Àü¸³¼±¾Ï (high grade prostate cancer; HGPC, Gleason grade 4 ÀÌ»ó)ÀÇ À¯º´·üÀÌ ³ô´Ù´Â Á¡¿¡¼­´Â ±× Àǹ̰¡ °¨¼ÒµÉ ¼ö¹Û¿¡ ¾ø´Ù.2 Finasteride°¡ °ú¿¬ °íµî±Þ¾ÏÀ» À¯¹ßÇÏ´ÂÁö¿¡ ´ëÇؼ­´Â ÇöÀç±îÁöµµ ¸¹Àº ³í¶õ°Å¸®·Î ³²¾ÆÀÖÀ¸¸ç,3 finasteride Åõ¿©°¡ °á°úÀûÀ¸·Î °íµî±Þ¾ÏÀ» À¯¹ßÇÑ´Ù´Â ¼³¸í¿¡ ´ëÇÑ ¿©·¯ °¡Áö ¹Ý·ÐÀÌ ÀÖÁö¸¸ ±× °¡¼³ ÁßÀÇ Çϳª·Î Àü¸³¼±ÀÇ Å©±â°¡ Á¶Á÷ÇÐÀû °Ë»çÀÇ °á°ú¿¡ ¿µÇâÀ» ¹ÌÃÆÀ» °¡´É¼ºÀÌ ¸¹´Ù´Â Á¡ÀÌ´Ù. Áï finasteride Åõ¿©±º¿¡¼­´Â Àü¸³¼± Å©±â °¨¼Ò¸¦
¾ß±âÇÏ¿´´Âµ¥, °íµî±Þ¾ÏÀÌ ÀÛÀº Àü¸³¼±¿¡¼­ ´õ Àß ¹ß°ßÀÌ µÇ°í °úÀ×À¸·Î Áø´ÜµÇ¾úÀ» °¡´É¼ºÀÌ ¸¹´Ù´Â °ÍÀÌ´Ù

Purpose: A prostate cancer prevention trial has demonstrated a higher incidence of high-grade prostate cancers(HGPC, Gleason pattern 4 or greater) among men randomized to receive treatment with finasteride. One of the hypotheses was finasteride causes a detection bias with regards to HGPC by reducing the prostate volume. We investigated the relationship between prostate volume and HGPC in prostate biopsy specimens and prostatectomy specimens(RP) from the same patients.

Materials and methods: We retrospectively reviewed a cohort of 173 consecutive patients that underwent a radical prostatectomy. We identified risk factors for HGPC on 12 core needle biopsies and then on RP specimens using univariate and multivariate logistic regression analysis. In transrectal ultrasound(TRUS) volume quartiles, the relationship of HGPC and prostate volume was analyzed between the lowest and the highest quartile.

Results:By multivariate analysis, risk factors of HGPC were age and prostate-specific antigen(PSA), but TRUS volume was not associated with HGPC in both biopsy and RP specimens. In TRUS volume quartiles, the relationship of HGPC and prostate volume was not significant. In addition, in a comparison of the lowest and the highest quartile, the relationship of HGPC and prostate volume was not significant.

Conclusions:Prostate volume may not be significantly associated with the grade of prostate cancers diagnosed at 12 core(or more) needle biopsies and at a radical prostatectomy. (Korean J Urol 2007;48:1004-1009)

Å°¿öµå

Prostate;Prostatic neoplasms;Biopsy;Needle

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS